Literature DB >> 21326256

Pharmacogenomics at the tipping point: challenges and opportunities.

D M Roden, R F Tyndale.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21326256     DOI: 10.1038/clpt.2010.340

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  8 in total

1.  A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.

Authors:  J H Choi; S W Yee; A H Ramirez; K M Morrissey; G H Jang; P J Joski; J A Mefford; S E Hesselson; A Schlessinger; G Jenkins; R A Castro; S J Johns; D Stryke; A Sali; T E Ferrin; J S Witte; P-Y Kwok; D M Roden; R A Wilke; C A McCarty; R L Davis; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2011-09-28       Impact factor: 6.875

2.  A semi-supervised approach to extract pharmacogenomics-specific drug-gene pairs from biomedical literature for personalized medicine.

Authors:  Rong Xu; Quanqiu Wang
Journal:  J Biomed Inform       Date:  2013-04-06       Impact factor: 6.317

3.  The value proposition of molecular medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

4.  Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.

Authors:  J S Schildcrout; J C Denny; E Bowton; W Gregg; J M Pulley; M A Basford; J D Cowan; H Xu; A H Ramirez; D C Crawford; M D Ritchie; J F Peterson; D R Masys; R A Wilke; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-06-27       Impact factor: 6.875

5.  Assessment of healthcare students' views on pharmacogenomics at the University of Minnesota.

Authors:  Meg Moen; Jatinder Lamba
Journal:  Pharmacogenomics       Date:  2012-10       Impact factor: 2.533

6.  Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Authors:  S Mahurkar; M Moldovan; V Suppiah; M Sorosina; F Clarelli; G Liberatore; S Malhotra; X Montalban; A Antigüedad; M Krupa; V G Jokubaitis; F C McKay; P N Gatt; M J Fabis-Pedrini; V Martinelli; G Comi; J Lechner-Scott; A G Kermode; M Slee; B V Taylor; K Vandenbroeck; M Comabella; F M Boneschi; C King
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

7.  Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.

Authors:  Tianbo Jin; Xugang Shi; Li Wang; Huijuan Wang; Tian Feng; Longli Kang
Journal:  BMC Genet       Date:  2016-05-28       Impact factor: 2.797

Review 8.  Personalizing health care: feasibility and future implications.

Authors:  Brian Godman; Alexander E Finlayson; Parneet K Cheema; Eva Zebedin-Brandl; Inaki Gutiérrez-Ibarluzea; Jan Jones; Rickard E Malmström; Elina Asola; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Bucsics; Stephen Campbell; Eduardo Diogene; Alessandra Ferrario; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Katharine Harris; Alan Haycox; Harald Herholz; Krystyna Hviding; Saira Jan; Marija Kalaba; Christina Kvalheim; Ott Laius; Sven-Ake Lööv; Kamila Malinowska; Andrew Martin; Laura McCullagh; Fredrik Nilsson; Ken Paterson; Ulrich Schwabe; Gisbert Selke; Catherine Sermet; Steven Simoens; Dominik Tomek; Vera Vlahovic-Palcevski; Luka Voncina; Magdalena Wladysiuk; Menno van Woerkom; Durhane Wong-Rieger; Corrine Zara; Raghib Ali; Lars L Gustafsson
Journal:  BMC Med       Date:  2013-08-13       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.